Comparing the current results to its competitors, Cabaletta Bio Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 10.69 %, recorded in the same quarter.
Cabaletta Bio Inc 's Comment on Competition and Industry Peers
The company operates in the biotechnology and pharmaceutical industry, which is marked by rapid technological advancements and intense competition. Its competitors include large and specialty pharmaceutical and biotechnology companies, academic research organizations, and governmental agencies. Specifically, the company competes with Novartis Pharmaceuticals Corporation, Gilead Sciences, Inc., Bristol Myers Squibb, Johnson and Johnson, Inc., Legend Biotech Corporation, and Autolus, all of which have marketed CAR T therapies for hematologic cancers. Several of these companies, along with other biopharmaceutical firms, are developing CD19-targeting therapies and engineered T cell approaches for autoimmune diseases such as systemic lupus erythematosus (SLE), myositis, systemic sclerosis (SSc), and myasthenia gravis (MG). Additionally, other pharmaceutical and biotechnology companies are investigating CD19-CAR T cells, engineered T cells, natural killer cells, or bispecific antibodies for autoimmune conditions. Many competitors possess substantially greater financial resources and expertise in drug development and commercialization. Industry mergers and acquisitions may further consolidate resources among fewer competitors, while smaller or early-stage companies may also emerge as significant competitors.
February 18, 2025
Cabaletta Bio, a clinical-stage biotechnology company, is making significant strides in the development of innovative targeted cell therapies aimed at treating autoimmune diseases. Recent updates from the company highlight the encouraging clinical performance of their investigational therapy, CABA-201, particularly across a range of indications such as systemic lupus erythematosus (SLE), dermatomyositis, and renal conditions.At recent scientific meetings, Cabaletta Bio reported updated clinical data that underscores the continuation of positive clinical responses among patients treated with CABA-201. Notably, three patients diagnosed with systemic lupus erythematosus (SLE) have achieved remission status in t...
January 8, 2024
Philadelphia-based biopharmaceutical company, Cabaletta Bio, has recently announced that their investigational therapy, CABA-201, has been granted two new Fast Track Designations by the U.S. Food and Drug Administration (FDA) for the treatment of dermatomyositis and systemic sclerosis. This news follows the previous fast track designations for CABA-201 in systemic lupus erythematosus (SLE) and lupus nephritis (LN), demonstrating the potential of this therapy to address various autoimmune diseases.Fast Track Designation by the FDA is a program designed to facilitate the development and expedite the review process of drugs that address unmet medical needs, particularly those conditions that do not have effecti...
Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.
Genenta Science S.p.A. operates on a business model focused on the development of immuno-gene therapies for the treatment of cancer. They aim to leverage their proprietary technology to genetically modify autologous hematopoietic stem cells and engineer them to express immunomodulatory protein IL-12. These modified cells are then reinfused into patients to stimulate an immune response against tumors, potentially offering a novel and personalized approach to cancer treatment.
Fate Therapeutics Inc's business model revolves around the development and commercialization of innovative cell-based therapies to treat various diseases.
Curis Inc's business model revolves around the development and commercialization of innovative cancer therapies. They focus on discovering and advancing drug candidates targeting specific molecular pathways involved in cancer growth and survival. The company collaborates with pharmaceutical partners to conduct clinical trials and seek regulatory approval for their products.
Celularity is a biotechnology company that focuses on developing and delivering transformative cellular therapies for various diseases. Their business model encompasses acquiring and licensing cellular assets, conducting research and development to advance these therapies, and forming strategic partnerships with healthcare organizations and research institutions to commercialize and distribute their innovative products. Through this model, Celularity aims to address unmet medical needs and provide novel therapies to improve patient outcomes.
Sources:
Cabaletta Bio Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Cabaletta Bio Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
